Covidien To Exit OneShot&#0153 Renal Denervation Program

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced it will exit its OneShotâ„¢ Renal Denervation program. This voluntary action is primarily in response to slower than expected development of the renal denervation market. The OneShot system is an over-the-wire balloon-based irrigated catheter technology for the treatment of hypertension. The system received CE Mark in February 2012 and is not approved for sale in the United States.

Help employers find you! Check out all the jobs and post your resume.

Back to news